RecruitingPhase 2NCT07509749

Novel Therapies for Severe Acute GVHD (Graft-versus-host Disease)

Prospective Randomized Controlled Trial of Novel Therapies for Severe Acute GVHD (Graft-versus-host Disease)

Sponsor

Daihong Liu

Enrollment

54 participants

Start Date

Jun 30, 2025

Study Type

INTERVENTIONAL

Conditions

GVHD,Acute Stem Cell Transplant Complications

Summary

The purpose of this study is to determine the efficacy and safety of combined Ruxolitinib With Corticosteroids as First Line Therapy for the severe acute GVHD (graft-versus-host disease )

Eligibility

Min Age: 14 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Methylprednisolone and a drug called Ruxolitinib and Methylprednisolone for people with gvhd,acute and stem cell transplant complications. The study is currently recruiting participants at 1 location. People eligible for this study include aged 14 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRuxolitinib and Methylprednisolone

Participants began oral administration of ruxolitinib at 5 mg QD; Methylprednisolone (1mg/kg)

DRUGMethylprednisolone

Methylprednisolone 2mg/kg/d , iv or iv gtt for at least 1 week, then taper according to the clinical response.

Locations(1)

Department of Hematology, the Fifth Center of Chinese PLA General Hospital

Beijing, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07509749

Related Trials

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

NCT0339436571 locations

CXCL9 and EASIX for Prediction of Acute Graft Versus Host Disease

NCT057187911 location

Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor

NCT032143541 location

A Novel Digital Application (SHIFT) to Improve Outcomes for Hematopoietic Stem Cell Transplant Survivors

NCT065410023 locations

Intestinal Microbiota in Stem Cell Transplant Transplant Admission

NCT046234241 location